Trial Profile

A Phase I Study to Assess Biodistribution of 89Zr-CB307 in PSMA+ and PSMA- Tumour Lesions (A Sub-study of CBT307-1 Study - EUDRACT 2019-004584-46)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CB 307 (Primary)
Indications Prostate cancer; Solid tumours
Focus Adverse reactions; Pharmacokinetics
Sponsors Crescendo Biologics

Most Recent Events

14 Sep 2024 According to a Crescendo Biologics media release, data from this study were presented at the 2024 European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona from 13-17 September.
14 Sep 2024 Results presented in a Crescendo Biologics Media Release.
26 Feb 2024 Planned End Date changed from 1 Dec 2023 to 31 Oct 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com